Biotek-snakken — Marts 2021
-
lahn1: https://finance.yahoo.com/quote/CHMA?p=CHMA&.tsrc=fin-srch nævnes på YAHOO's finance, så er rigelig omkring sig! Oppe i premarked ~11%
-
Var der ikke lige nogen som droppede en FRa trial, kommende partner ? Vi skal vel også have bevis på at STRO-002 faktisk virker på FRa medium og high ved escalation data i 1H2020. Måske er der "bare" en immune effekt ? Tror du ikke vi skal have expansion data før der udlicensering sker, altså 2H2020 ?
-
Den skal vel kombineres med en PD-1 inhibitor, jf. sidste års AACR: https://www.adcreview.com/news/preclinical-data-suggests-synergy-between-stro-002-and-immune-checkpoint-inhibitors-resulting-in-tumor-regression-and-adaptive-anti-tumor-immunity/. Den gang sagde de endda "We currently expect to initiate an STRO-002 combination clinical trial in 2021"
-
Så spændende om en combination partner også vil overtage rettigheder til STRO-002
-
Ja tak Lassevedel96, det vil vi gerne have noget mere af . These data suggest that STRO-002 can drive immune-modulatory responses that can cause complete tumor regression, tumor-specific T-cell activation, and adaptive anti-tumor immunity,” noted Sutro’s Chief Scientific Officer, Trevor Hallam, Ph.D
-
Og timing på com
bination study er yderligere præciseret til 2021H2 i deres corporate presentation: https://www.sutrobio.com/wp-content/uploads/2020/12/SutroBiopharma_March-2021-vFINAL.01-compressed.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind